Antisense oligonucleotides: progress, opportunities and challenges-Reference-Cited by-同舟云学术

Antisense oligonucleotides: progress, opportunities and challenges

Published:2013-11 Issue: Volume: Page:6-22
ISSN:
Container-title:Nucleic Acid-Based Drugs
language:
Short-container-title:

Author:

Sanghvi Yogesh S¹

Affiliation:

1. Yogesh S Sanghvi is the Founder and President of Rasayan Inc. (CA, USA). He is engaged in the consulting, outsourcing services and supply of products related to the nucleic acid field. His specific interests include the design, synthesis, chemistry and biochemistry of novel carbohydrates, nucleosides, nucleotides and oligonucleotides for their application in therapeutics and medical diagnostic research. He has over 150 scientific publications in leading journals, including several book chapters, and has...

Publisher

Future Science Ltd

Link

http://www.future-science.com/doi/pdf/10.4155/ebo.13.412

Reference24 articles.

1. Sanghvi YS . A status update of modified oligonucleotides for chemotherapeutic applications. In: Current Protocols in Nucleic Acid Chemistry Egli M, Herdewijn P, Matsuda A, Sanghvi YS (Eds) . John Wiley & Sons , NJ, USA , 4.1 – 4.1.22 (2011) .

2. Prediction of antisense oligonucleotides using structural and thermodynamic motifs

3. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

4. Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nucleic acid-based drugs against emerging zoonotic viruses;Future Medicinal Chemistry;2015-09